Carvedilol blocks neural regulation of breast cancer progression in  vivo and is associated with reduced breast cancer mortality in patients

The sympathetic nervous system drives breast cancer progression through β-adrenergic receptor signalling. This discovery has led to the consideration of cardiac β-blocker drugs as novel strategies for anticancer therapies. Carvedilol is a β-blocker used in the management of cardiovascular disorders, anxiety, migraine and chemotherapy-induced cardiotoxicity. However, little is known about how carvedilol affects cancer-related outcomes.

Source: European Journal of Cancer - February 24, 2021 Category: Cancer & Oncology Authors: Ryan D. Gillis, Edoardo Botteri, Aeson Chang, Alexandra I. Ziegler, Ni-Chun Chung, Cindy K. Pon, David M. Shackleford, Bettina K. Andreassen, Michelle L. Halls, Jillian G. Baker, Erica K. Sloan Tags: Original Research Source Type: research